Purpose Patients who develop prostate cancer after prior abdominal perineal resection are poor surgical candidates, and have limited treatment options. Therefore, our goal is to present results from a single institutional experience of four patients who underwent whole gland MRI-guided cryoablation with a history complicated by prior abdominoperineal resection. Materials and Methods Four MRI-guided cryoablative treatments (mean age 64, range 59-69 years) for primary and locally recurrent prostate adenocarcinoma were retrospectively reviewed in patients with prior abdominal perineal resection for colorectal cancer (3) and juvenile polyposis (1). Average prostate volume prior to ablation was 23 cc, with an average PSA of 5.6 ng/mL. For each gland, 7-10 cryoprobes were placed approximately 0.5 cm apart in the prostate gland under MRI guidance by a transperineal approach with 3-4 freeze-thaw cycles performed. Each patient had follow up imaging and PSA measurements out to 12 months post ablation. Results All four patient's PSA dropped below 0.1 ng/mL at 3-6 month post-ablation and remained at these levels at 12 months. Three of the 4 patients had PSA measurements to 33 months post-ablation, with no evidence of recurrence. No patient developed urinary incontinence due to the whole gland cryoablation. Conclusion With all four patients in our study having undetectable PSAs 12 months post ablation, and with no patient developing urinary incontinence due to the cryoablation, MRI-guided cryoablation appears to be a promising treatment option in patients who are poor surgical candidates due to prior pelvic surgery and/or radiation.
Introduction
In 2016, an estimated number of 70,820 new cases of colorectal cancer and 180,810 new cases of prostate cancer will be diagnosed [1] . Due to the high prevalence of colorectal cancer, it is not surprising that many patients survive one cancer only to get a second cancer. For many patients with colorectal cancer, especially in the distal colon or rectum, surgery is augmented with radiation to the pelvis. A history of prior pelvic surgery and radiation can complicate a subsequent prostate surgery or render the patient inoperable. In addition, repeat radiation therapy may or may not be an option for these patients. It has been shown that patients with prior pelvic radiation who undergo subsequent prostatectomy have increased complication rates [2, 3] . In this select population, an alternative to the standard therapy is necessary.
Prior studies have looked at the effectiveness of ultrasound guided salvage focal or total cryoablation in patients with recurrent prostate cancer in the setting of prior external beam radiation [4] [5] [6] . One such study, with 25 patients undergoing total salvage cryoablation for recurrent prostate cancer, demonstrated biochemical failure of 12% at 53 months of follow-up [4] . These results are promising; however, 13% of patients experienced new urinary incontinence [4] . This may be related to the limited resolution of the urethra provided by ultrasound monitoring during the freezing.
Magnetic resonance imaging (MRI) has emerged not only as a modality of choice for diagnosing prostate cancer, but also as a powerful intraprocedural imaging platform for percutaneous cryoablations, including lesion targeting and multiplanar monitoring of ice ball growth in proximity to sensitive structures (i.e., urethra, rectum, and nerve bundles), and visualization of the ablation coverage relative to tumor margin [7] . MRI has been demonstrated to be capable of delineating, with a high degree of accuracy, the edge of the ice ball, and to be robust in differentiation of normal from frozen tissues in all pulse sequences [8] [9] [10] . This allows the physician to select and tailor the pulse sequence to best visualize the tumor and related structures without having to be concerned about whether the ice edge can be seen [8] [9] [10] .
MR targeting and monitoring of cryoablation offer potential advantages over ultrasound guidance and monitoring; however, the published data on whole-gland MRIguided cryoablation are limited. Therefore, our goal is to present results from a single institutional experience of four patients with a history complicated by prior abdominoperineal resection secondary to colorectal cancer and juvenile polyposis who subsequently underwent whole-gland MRI-guided cryoablation due to limited/increased potential complications of standard treatment strategies.
Materials and Methods
Following approval from our institutional review board, we retrospectively analyzed four MRI-guided cryoablative treatments (mean age 64, range 59-69 years) for primary and locally recurrent prostate adenocarcinoma (Table 1 ). All four patients had prior abdominal perineal resection for colorectal cancer (3) and juvenile polyposis (1) . Two of the four patients had subsequent chemotherapy and radiation therapy for prior colorectal cancer. One patient had abdominal perineal resection and radiation therapy for colorectal cancer and subsequently had prostate cancer treated with external beam radiation therapy. The patients were evaluated by the urology surgical team and were deemed poor surgical and radiation candidates given prior abdominal perineal resection and radiation history which is why they were offered the option of MRI-guided cryoablation.
The average prostate volume prior to ablation was 23 cc (range 18-28 cc). All of the patients had prostate MRI imaging prior to the cryoablation demonstrating hyperenhancing nodules with positive confirmation biopsy showing a Gleason score range from 6 to 7, with three patients with a Gleason score of 7 and one patient with a Gleason score of 6. Two of the four patients had transrectal ultrasound guided (TRUS) prostate biopsies, one patient had CT guided prostate biopsy, and one patient had digital Number of cryoprobes used
Mean 9
Median 10 Range 7-10 guidance biopsy, as this patient had a rectal stricture from prior surgery and was thought to be unsafe for TRUS. One of the four patients had a workup PET Choline C-11 scan that was negative for metastatic disease, and another two patients had whole-body nuclear medicine bone scans that were negative for osseous metastatic disease. The one patient who did not have whole-body metastatic disease imaging workup had a history of juvenile polyposis status post-proctocolectomy, with a recent new diagnosis of prostate cancer. This patient did have prior contrast-enhanced abdomen/pelvis CT's which were negative for metastatic disease. Mean prostate-specific antigen (PSA) was 5.6 ng/mL prior to treatment (Table 1) .
Procedure
In all four cases, patient consent was first obtained following extensive discussions regarding the details of the relatively novel MRI-guided cryoablation procedure. Following consent, MRI-guided cryoablation of the whole prostate gland was performed successfully for each of the patients. Three of the four patients started in the surgical operating room with placement of a suprapubic urinary catheter and were subsequently brought down to the MRI suite while intubated and under general anesthesia. One of the four patients did not have a suprapubic catheter placed so general anesthesia was initiated in the MRI anteroom. The procedure was performed using a clinical 70-cm internal bore 1.5T MRI (Magnetom Espree, Siemens Healthineers, Erlangen, Germany) scanner. The patient was positioned in a semi-frog leg position and then the perineum prepped and draped in a sterile fashion. A urethral warming catheter was then placed in order to help mitigate damage to the urethra. Cryoprobe deployment into target tissues was accomplished with the aid of a transperineal guidance grid (BioTex Inc, Houston, TX) placed against the patient's perineum. Following guidance grid placement, limited T2-weighted axial, equilibrium-driven turbo spin echo images were obtained for needle placement planning (TR/TE 4860/119 ms, Turbo Factor 22, matrix 256 9 256, FOV read 220 mm, FOV phase 100%, slice thickness 5 mm, distance factor 0%, bandwidth 140 Hz/Px, scan time 4 min 5 s). The overlay of the guidance grid was manually fused with the images, allowing needle paths to be selected. MR compatible cryoprobes (Galil Medical Inc, Minneapolis, MN) were tested for structural integrity under saline submersion. Cryoprobes were then placed in the selected grid holes and advanced with intermittent MRI guidance, using T2-weighted turbo spin echo images (TR/ TE 2320/100 ms, Turbo Factor 27, matrix 256 9 152, FOV 220 mm, slice 8 mm, distance factor 20%, bandwidth 349 Hz/Px, scan time 50 s). Multiplanar reformats were used for tip placement confirmation. Three of the four patients had three freeze-thaw cycles, with active thawing. One patient had four freeze-thaw cycles, due to necessity to reposition cryoprobes after two cycles in order to achieve improved coverage of the prostate gland. Active MRI monitoring was performed during the freezing process, which allowed near-continuous monitoring of the ice edge to ensure both the complete prostate cancer coverage (i.e., ice edge at least 5 mm beyond the visualized cancer lesions) and limiting ablation in the vicinity of the urethra or rectum (Fig. 1) . During freezing, the ice ball was monitored with T2-weighted turbo spin echo sequences (TR/TE 2320/100 ms, Turbo Factor 27, matrix 256 9 152, FOV 220 mm, slice 8 mm, distance factor 20%, bandwidth 349 Hz/Px, scan time 50 s). Due to the ease and high fidelity of ice edge monitoring with MR imaging on all aspects, the prostate was treated, but the ice edge was prevented from advancing into the nerve bundles.
Following the final thaw, all needles were removed. The final post-ablation imaging was performed using multiplanar T2-weighted, contrast-enhanced, and diffusionweighted images. The urethral warmer was then removed and replaced with a Foley catheter (16 Fr). The patients were subsequently transferred out of the MRI suite and extubated. All four patients were admitted to the hospital for 1 to 2 days post-ablation. The three patients with the suprapubic catheters had the catheter in place for three to 8 days and were removed after a voiding trial. The one patient who had only a Foley catheter during the procedure had it removed 4 days post-ablation.
Results
Four patients were treated with MRI-guided whole prostate gland cryoablation for biopsy-proven localized prostate cancer. All four patients had prior abdominal perineal resection, thus limiting their treatment options. Three of the four patients had prior radiation to the pelvis. Two of the four patients had a history of abdominal perineal resection for prior colorectal cancer, with subsequent chemotherapy and radiation therapy. One patient had prior abdominal perineal resection for prior colorectal cancer with radiation and subsequent radiation therapy for prostate cancer. Last, one patient had a history of juvenile polyposis status postproctocolectomy with subsequent development of prostate cancer.
Prostatic biopsies were performed either under CT guided transgluteal (1/4), ultrasound guided transrectal (2/4), or under digital guidance, as this patient had a rectal stricture and was thought to be unsafe for transrectal guidance. In each of these cases, there was MRI-based concern for bilateral multifocal disease limited to the prostate gland. For this reason, the whole gland was targeted for cryoablation. All patients treated with MRI-guided cryoablation had no known extra prostatic bed metastatic disease at the time of treatment. Two of the patients had negative nuclear medicine bone scans, and one patient had negative choline PET/CT prior to cryoablation.
Pre-procedure PSA mean was 5.6 ng/mL, range of 4.3-8.6 ng/mL (Table 1) . At 3-6-month follow-up, all four patients had a PSA \ 0.1 ng/mL. The PSA remained undetectable in all four patients at 12-month follow-up. Three of the four patients have follow-up out to 33 months, with the PSA remaining undetectable, \ 0.1 ng/mL. All four patients survived the year following the MRI-guided prostate cryoablation.
One of the patients is currently 6 years post-ablation, with last documented PSA measurement 4 years postablation, being undetectable. Imaging follow-up in this patient includes MRIs at 3 months, 1 year, and 2 years post-ablation, all negative for recurrence, and F18-FDG PET scan 2 years post-ablation, also negative for recurrent or metastatic disease. Pre-ablation MRI demonstrated a 13 9 7 9 7 mm (anterior posterior, transverse, coronal) enhancing focus in the right posterolateral prostate, near the apex. This lesion had low T1 signal and high T2 signal, with restricted diffusion and mild ill-defined peripheral enhancement with fibrous tissue (PIRADS 4). CT guided biopsy was revealing of Gleason 6 prostate cancer involving 5% on the right and atypical small acinar cells on the left. Three months post-ablation MRI in this patient was revealing of high T1 and T2 signals throughout the prostate. One year post-ablation MRI was revealing of fluid signals and non-enhancing tissue, with a similar appearance 2 years post-ablation. performed for examination of needle position (small signal voids, white arrowhead) relative to the urethra which has the urethral warming catheter (asterisk) within it. D Subsequent axial Vibe image demonstrating the extent of the ice ball as a large signal void. E Postablation dynamic contrast-enhanced Vibe showing a relative lack of enhancement within the prostate gland. F 6 months post-ablation contrast-enhanced T1-weighted LAVA-flex image at 3T demonstrates post-ablation changes with no hyper-enhancing foci Another patient is 5 years post-ablation, with PSA remaining undetectable. Pre-ablation MRI was positive for an 8 9 10 9 5 mm enhancing nodule on the right side of the prostate, near the apex. This nodule had low T1 and high T2 signal, with restricted diffusion (PIRADS 4). Digital guided biopsy was revealing of Gleason 7 prostate adenocarcinoma throughout the right side of the prostate, including the anterior apex, anterior and posterior base. The left posterior base was positive for focal high-grade prostate intraepithelial neoplasia. This patient did not have follow-up imaging.
The third patient is 3 years post-ablation, with last documented PSA 3 years post-ablation, being undetectable. Imaging follow-up in this patient includes MRIs at 6 months, 2, and 3 years, all negative for recurrent disease. Pre-ablation MRI displayed diffuse ill-defined hyper-intense T2 signal, with loss of zonal anatomy from postradiation changes. There was a 9 mm enhancing focus in the left side of the prostate, in the mid peripheral zone. This lesion had restricted diffuse (PIRADS 4). TRUS biopsy revealed 7/11 cores from the left lobe positive for Gleason 7 prostate cancer, with 1/6 cores from the right lobe positive. Post-ablation MRI at 3 months was revealing of patchy, bilateral, prostate hemorrhage, which is resolved by 3-year follow-up MRI. There were no enhancing foci.
The last patient passed away 3 years following prostate cryoablation from acute liver failure in the setting of chronic alcoholic cirrhosis. Pre-ablation MRI was revealing of radiation changes throughout the prostate with focal decreased T2 signal at the base of the prostate, with no abnormal enhancement. The bilateral peripheral and mid zones showed diffusely increased enhancement, but without abnormal T2 or restricted diffusion. TRUS biopsy was revealing of Gleason 7 prostatic adenocarcinoma in 4/7 cores from the right lobe and 5/7 cores in the left lobe, with perineural invasion, but no extra prostatic extension. Postablation MRIs done at 6 months and 1 year were revealing of stable, asymmetric T2 hypointensity of the left prostate, but no restricted diffusion or enhancement in this area. The last documented PSA was 1 year post-ablation and was undetectable.
Changes in urinary symptoms were monitored through history. Prior to ablation, all of the patients were questioned about urinary symptoms or erectile dysfunction. Post-ablation follow-up questions about changes in symptoms were also asked. Two of the four patients had no change in urinary symptoms or erectile dysfunction due to the cryoablation, with one patient reporting new dribble incontinence not requiring the use of pads and one patient reporting increased erectile dysfunction (successfully treated with phosphodiesterase inhibitor). No patient developed urinary incontinence due to the whole-gland cryoablation.
Discussion
The standard treatment of prostatectomy or radiation therapy for native prostate cancer becomes complicated for patients with prior pelvic surgery and/or radiation due to other malignancies [2, 3] . In these patients, MRI-guided cryoablation offers a potential alternative treatment option for these patients. In this study, four patients were treated with whole-gland MRI-guided cryoablation with undetectable PSAs at 1 year.
There are several limitations of this study, the greatest being the retrospective nature without appropriately matched controls and also the small number of cases performed and the lack of long-term (greater than 5 years) follow-up. Continued prospective analysis of new wholegland prostate ablation cases and long-term follow-up results are areas for future study.
This small cohort of patients exemplifies the difficulties encountered by patients who develop prostate cancer after already undergoing treatment for colorectal cancer. MRguided cryoablation offers the potential for additional treatment where very few treatment options are available. With all four patients having undetectable PSAs 12 months post-ablation, and three of these four patients continuing to having undetectable PSAs at 33 months, MRI-guided cryoablation appears to be a promising treatment for prostate cancer in this select patient population with limited treatment options. Furthermore, the MRI guidance allows increased safety due to precise monitoring of the ice edge advancement. This is reflected in the low levels of worsened urinary incontinence and impotence symptoms following the cryoablation procedures.
Compliance with Ethical Standards
Conflict of interest On behalf of all authors, the corresponding author states that there is no conflict of interest.
Ethical Approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed Consent Informed consent was obtained from all individual participants included in the study.
